Literature DB >> 25224012

NS5A inhibitors impair NS5A-phosphatidylinositol 4-kinase IIIα complex formation and cause a decrease of phosphatidylinositol 4-phosphate and cholesterol levels in hepatitis C virus-associated membranes.

V Reghellin1, L Donnici1, S Fenu1, V Berno1, V Calabrese2, M Pagani1, S Abrignani1, F Peri2, R De Francesco3, P Neddermann3.   

Abstract

The hepatitis C virus (HCV) nonstructural (NS) protein 5A is a multifunctional protein that plays a central role in viral replication and assembly. Antiviral agents directly targeting NS5A are currently in clinical development. Although the elucidation of the mechanism of action (MOA) of NS5A inhibitors has been the focus of intensive research, a detailed understanding of how these agents exert their antiviral effect is still lacking. In this study, we observed that the downregulation of NS5A hyperphosphorylation is associated with the actions of NS5A inhibitors belonging to different chemotypes. NS5A is known to recruit the lipid kinase phosphatidylinositol 4-kinase IIIα (PI4KIIIα) to the HCV-induced membranous web in order to generate phosphatidylinositol 4-phosphate (PI4P) at the sites of replication. We demonstrate that treatment with NS5A inhibitors leads to an impairment in the NS5A-PI4KIIIα complex formation that is paralleled by a significant reduction in PI4P and cholesterol levels within the endomembrane structures of HCV-replicating cells. A similar decrease in PI4P and cholesterol levels was also obtained upon treatment with a PI4KIIIα-targeting inhibitor. In addition, both the NS5A and PI4KIIIα classes of inhibitors induced similar subcellular relocalization of the NS5A protein, causing the formation of large cytoplasmic NS5A-containing clusters previously reported to be one of the hallmarks of inhibition of the action of PI4KIIIα. Because of the similarities between the effects induced by treatment with PI4KIIIα or NS5A inhibitors and the observation that agents targeting NS5A impair NS5A-PI4KIIIα complex formation, we speculate that NS5A inhibitors act by interfering with the function of the NS5A-PI4KIIIα complex.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25224012      PMCID: PMC4249536          DOI: 10.1128/AAC.03293-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  59 in total

1.  Phosphatidylinositol-4 kinase III beta and oxysterol-binding protein accumulate unesterified cholesterol on poliovirus-induced membrane structure.

Authors:  Minetaro Arita
Journal:  Microbiol Immunol       Date:  2014-04       Impact factor: 1.955

2.  Hepatitis C virus NS5A protein interacts with phosphatidylinositol 4-kinase type IIIalpha and regulates viral propagation.

Authors:  Yun-Sook Lim; Soon B Hwang
Journal:  J Biol Chem       Date:  2011-02-05       Impact factor: 5.157

3.  Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052.

Authors:  Robert A Fridell; Dike Qiu; Lourdes Valera; Chunfu Wang; Ronald E Rose; Min Gao
Journal:  J Virol       Date:  2011-05-18       Impact factor: 5.103

4.  Crystal structure of a novel dimeric form of NS5A domain I protein from hepatitis C virus.

Authors:  Robert A Love; Oleg Brodsky; Michael J Hickey; Peter A Wells; Ciarán N Cronin
Journal:  J Virol       Date:  2009-02-25       Impact factor: 5.103

5.  The alpha isoform of protein kinase CKI is responsible for hepatitis C virus NS5A hyperphosphorylation.

Authors:  Manuela Quintavalle; Sonia Sambucini; Chiara Di Pietro; Raffaele De Francesco; Petra Neddermann
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

6.  Characterizations of HCV NS5A replication complex inhibitors.

Authors:  Donald R O'Boyle Ii; Jin-Hua Sun; Peter T Nower; Julie A Lemm; Robert A Fridell; Chunfu Wang; Jeffrey L Romine; Makonen Belema; Van N Nguyen; Denis R St Laurent; Michael Serrano-Wu; Lawrence B Snyder; Nicholas A Meanwell; David R Langley; Min Gao
Journal:  Virology       Date:  2013-07-27       Impact factor: 3.616

7.  Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.

Authors:  Carola Berger; Inés Romero-Brey; Danijela Radujkovic; Raphael Terreux; Margarita Zayas; David Paul; Christian Harak; Simone Hoppe; Min Gao; Francois Penin; Volker Lohmann; Ralf Bartenschlager
Journal:  Gastroenterology       Date:  2014-07-18       Impact factor: 22.682

8.  Viral reorganization of the secretory pathway generates distinct organelles for RNA replication.

Authors:  Nai-Yun Hsu; Olha Ilnytska; Georgiy Belov; Marianita Santiana; Ying-Han Chen; Peter M Takvorian; Cyrilla Pau; Hilde van der Schaar; Neerja Kaushik-Basu; Tamas Balla; Craig E Cameron; Ellie Ehrenfeld; Frank J M van Kuppeveld; Nihal Altan-Bonnet
Journal:  Cell       Date:  2010-05-28       Impact factor: 41.582

9.  Inhibition of HCV replication by oxysterol-binding protein-related protein 4 (ORP4) through interaction with HCV NS5B and alteration of lipid droplet formation.

Authors:  In-Woo Park; Jean Ndjomou; Yahong Wen; Ziqing Liu; Neale D Ridgway; C Cheng Kao; Johnny J He
Journal:  PLoS One       Date:  2013-09-17       Impact factor: 3.240

10.  HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus.

Authors:  Norman M Kneteman; Anita Y M Howe; Tiejun Gao; Jamie Lewis; Dan Pevear; Gary Lund; Donna Douglas; David F Mercer; D Lorne J Tyrrell; Frederick Immermann; Inder Chaudhary; John Speth; Stephen A Villano; John O'Connell; Marc Collett
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

View more
  14 in total

Review 1.  Lipid Tales of Viral Replication and Transmission.

Authors:  Nihal Altan-Bonnet
Journal:  Trends Cell Biol       Date:  2016-11-09       Impact factor: 20.808

Review 2.  Targeting host lipid synthesis and metabolism to inhibit dengue and hepatitis C viruses.

Authors:  Valerie A Villareal; Mary A Rodgers; Deirdre A Costello; Priscilla L Yang
Journal:  Antiviral Res       Date:  2015-10-23       Impact factor: 5.970

3.  Cyclophilin and NS5A inhibitors, but not other anti-hepatitis C virus (HCV) agents, preclude HCV-mediated formation of double-membrane-vesicle viral factories.

Authors:  Udayan Chatterji; Michael Bobardt; Andrew Tai; Malcolm Wood; Philippe A Gallay
Journal:  Antimicrob Agents Chemother       Date:  2015-02-09       Impact factor: 5.191

Review 4.  Mechanisms of Hepatitis C Viral Resistance to Direct Acting Antivirals.

Authors:  Asma Ahmed; Daniel J Felmlee
Journal:  Viruses       Date:  2015-12-18       Impact factor: 5.048

Review 5.  Hepatitis C virus life cycle and lipid metabolism.

Authors:  Costin-Ioan Popescu; Laura Riva; Ovidiu Vlaicu; Rayan Farhat; Yves Rouillé; Jean Dubuisson
Journal:  Biology (Basel)       Date:  2014-12-15

6.  Mutations in Encephalomyocarditis Virus 3A Protein Uncouple the Dependency of Genome Replication on Host Factors Phosphatidylinositol 4-Kinase IIIα and Oxysterol-Binding Protein.

Authors:  Cristina M Dorobantu; Lucian Albulescu; Heyrhyoung Lyoo; Mirjam van Kampen; Raffaele De Francesco; Volker Lohmann; Christian Harak; Hilde M van der Schaar; Jeroen R P M Strating; Alexander E Gorbalenya; Frank J M van Kuppeveld
Journal:  mSphere       Date:  2016-05-11       Impact factor: 4.389

7.  NS5A inhibitors unmask differences in functional replicase complex half-life between different hepatitis C virus strains.

Authors:  Tiffany Benzine; Ryan Brandt; William C Lovell; Daisuke Yamane; Petra Neddermann; Raffaele De Francesco; Stanley M Lemon; Alan S Perelson; Ruian Ke; David R McGivern
Journal:  PLoS Pathog       Date:  2017-06-08       Impact factor: 6.823

8.  Hijacking of multiple phospholipid biosynthetic pathways and induction of membrane biogenesis by a picornaviral 3CD protein.

Authors:  Sravani Banerjee; David Aponte-Diaz; Calvin Yeager; Suresh D Sharma; Gang Ning; Hyung S Oh; Qingxia Han; Masato Umeda; Yuji Hara; Robert Y L Wang; Craig E Cameron
Journal:  PLoS Pathog       Date:  2018-05-21       Impact factor: 6.823

9.  Escaping Host Factor PI4KB Inhibition: Enterovirus Genomic RNA Replication in the Absence of Replication Organelles.

Authors:  Charlotte E Melia; Hilde M van der Schaar; Heyrhyoung Lyoo; Ronald W A L Limpens; Qian Feng; Maryam Wahedi; Gijs J Overheul; Ronald P van Rij; Eric J Snijder; Abraham J Koster; Montserrat Bárcena; Frank J M van Kuppeveld
Journal:  Cell Rep       Date:  2017-10-17       Impact factor: 9.423

10.  Phosphoproteomics Identified an NS5A Phosphorylation Site Involved in Hepatitis C Virus Replication.

Authors:  Weng Man Chong; Shih-Chin Hsu; Wei-Ting Kao; Chieh-Wen Lo; Kuan-Ying Lee; Jheng-Syuan Shao; Yi-Hung Chen; Justin Chang; Steve S-L Chen; Ming-Jiun Yu
Journal:  J Biol Chem       Date:  2015-12-23       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.